Search filters
Filters
Clear All

Phase

  • 1
  • 7
  • 8
  • 8
  • 8

Found 8 Bladder Carcinoma trials

A listing of Bladder Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A Phase 3 Randomized Comparator-Controlled Clinical Trial to Study the Efficacy of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)

99 years and younger
All genders
Phase 3
This study will involve patients with high risk non-muscle invasive bladder cancer (NMIBC) that is persistent (cancer stays) or recurrent (cancer comes back) following Bacillus Calmette-Guérin BCG treatment. The purpose of this study is to: o Test the safety of the study drugs, pembrolizumab in combination with Bacillus Calmette-Guerin (BCG) …
Learn More

EA8212 A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)

99 years and younger
All genders
The purpose of this study is to compare the usual treatment (BCG) to using gemcitabine + docetaxel in order to assess whether the treatments are similar in preventing recurrence of bladder cancer. But it could also cause side effects. The target population for this study is 20. We will utilize …
Learn More

EA8192 A Phase II/III trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy

99 years and younger
All genders
To determine the event free survival (EFS) of BCG-naïve high grade non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical BCG vs GEMDOCE. To compare changes in cancer-specific and bladder cancer-specific QOL from baseline to treatment between BCG-naïve high grade NMIBC patients receiving BCG and GEMDOCE. Target population is 20. …
Learn More

SunRISe-4

99 years and younger
All genders
The study is being conducted to research if an investigational drug delivery system (gemcitabine/TAR-200) in combination with intravenous cetrelimab and intravenous cetrelimab alone can improve the results of radical cystectomy for participants with muscle invasive bladder cancer.
Learn More

UPCC 23922 A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of H

99 years and younger
All genders
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head or Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
Learn More

A031501: Phase III randomized Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locally ADvanced urOthelial caRcinoma (AMBASSADOR) versus observation

99 years and younger
All genders
We would like to rely on the NCI CIRB as IRB of record for this study. The purpose of this study is to compare any good and bad effects of using a drug called MK-3475 (pembrolizumab) after the removal of muscle invasive bladder cancer.
Learn More

UPCC 09818: An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs. Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

99 years and younger
All genders
The main purpose of this study is to collect information to determine if a medicine called enfortumab vedotin (EV) is effective, safe and comparable to the docetaxel or paclitaxel for cancer of the urinary system (urothelial cancer, including cancer of the bladder, renal pelvis, ureter or urethra) that has spread …
Learn More

BCG at home

99 years and younger
All genders
The long-term goal of our research program is to identify and target the mechanisms by which innovations in care delivery may facilitate compliance with guideline-concordant care and access to care for early and late stage bladder cancer patients. The objective in this proposal is to evaluate a novel delivery model …
Learn More